Abstract

Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design

Author(s): Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S

Issue: Jan/Feb 2021 - Volume 25, Number 1

Page(s): 73-81

Download in electronic PDF format for $75
  • Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Page 1
  • Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Page 2
  • Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Page 3
  • Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Page 4
  • Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Page 5
  • Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Page 6
  • Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Page 7
  • Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Page 8
  • Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Page 9

Abstract

Trimix is a widely prescribed penile injection for patients with erectile dysfunction and is only available as a compounded medication. The instability of alprostadil, one of the major ingredients of Trimix, has been a limiting factor in its utilization. There are published stability data for Trimix formulations that have been used to establish a beyond-use-date. However, a robust bracketed study that is shown to be reproducible is highly desirable and meaningful. The purpose of this study was to test the reproducibility of a bracketed stability study when the preparations were made by two different entities to provide beyond-use date information of Trimix preparations that cover a wide range of strengths. A validated stability indicating method was used to compare the stability of a bracketed Trimix - alprostadil 5 µg/mL to 45 µg/mL, papaverine 15 mg/mL to 30 mg/mL, and phentolamine 0.4 mg/mL to 5 mg/mL, and a single-strength preparation containing alprostadil 30 µg/mL, papaverine 30 mg/mL, and phentolamine 2 mg/mL that were compounded and stored following the same methods and conditions, but at two different practice settings. Beyond-use dates of 60 days and 64 days at cold temperature were obtained for the two preparations from two different settings. The consistent results confirmed the reproducibility of the bracketing designs used to determine the beyond-use dates of Trimix. The clinical value of these results stems from the availability of accurate and widely applicable stability data that can be referenced to establish beyond use dates of a number of Trimix preparations with various strength combinations.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2021
Pg. 73-81
May/Jun 2004
Pg. 231-235
Jan/Feb 2021
Pg. 18-23
Mar/Apr 2018
Pg. 129-134
Author(s): Rhoads Rick
Mar/Apr 2021
Pg. 94-98
May/Jun 2003
Pg. 171
Author(s): Meece Jerry
Mar/Apr 1999
Pg. 134
Author(s): Allen Loyd V Jr
Mar/Apr 1999
Pg. 160-163
May/Jun 2021
Pg. 236-240
Nov/Dec 2014
Pg. 456-460
Mar/Apr 1997
Pg. 132-134
Mar/Apr 1999
Pg. 81
Author(s): Preckshot John
Nov/Dec 2012
Pg. 471-474
Author(s): Osteen Richard
Nov/Dec 2012
Pg. 507
Author(s): Allen Loyd V Jr
May/Jun 2003
Pg. 170-174
Author(s): Meece Jerry
Jul/Aug 2018
Pg. 303-312
Author(s): Martin Matt
Mar/Apr 2017
Pg. 150-153
Jul/Aug 2014
Pg. 345-347
Mar/Apr 2010
Pg. 105-107
Author(s): Williams LaVonn A
Mar/Apr 2007
Pg. 122-124
Author(s): Fields Shannon W